Velia Chiara Di Maio

We don’t have enough information about this author to calculate their statistics. If you think this is an error let us know.
Learn More
Available commercial assays may yield inaccurate hepatitis C virus (HCV) genotype assignment in up to 10% of cases. We investigated the cost-effectiveness of re-evaluating HCV genotype by population sequencing, prior to choosing a direct acting antiviral (DAA) regimen. Between March and September 2015, HCV sequence analysis was performed in order to confirm(More)
  • 1